Drug General Information
Drug ID
D04ECT
Former ID
DNC004790
Drug Name
4-Thiomorpholin-4-yl-benzo[g]chromen-2-one
Drug Type
Small molecular drug
Indication Discovery agent Investigative [527386]
Structure
Download
2D MOL

3D MOL

Formula
C17H15NO2S
Canonical SMILES
C1CSCCN1C2=CC(=O)OC3=CC4=CC=CC=C4C=C23
InChI
1S/C17H15NO2S/c19-17-11-15(18-5-7-21-8-6-18)14-9-12-3-1-2-4-13(12)10-16(14)20-17/h1-4,9-11H,5-8H2
InChIKey
UYBNTAODFKOXIU-UHFFFAOYSA-N
PubChem Compound ID
Target and Pathway
Target(s) DNA-dependent protein kinase catalytic subunit Target Info Inhibitor [527386]
KEGG Pathway Non-homologous end-joining
Cell cycle
NetPath Pathway IL1 Signaling Pathway
Pathway Interaction Database DNA-PK pathway in nonhomologous end joining
Coregulation of Androgen receptor activity
Class I PI3K signaling events mediated by Akt
BARD1 signaling events
Reactome Nonhomologous End-Joining (NHEJ)
WikiPathways DNA Damage Response
Non-homologous end joining
FAS pathway and Stress induction of HSP regulation
Cytosolic sensors of pathogen-associated DNA
Retinoblastoma (RB) in Cancer
Prostate Cancer
Double-Strand Break Repair
Cell Cycle
miRNA Regulation of DNA Damage Response
References
Ref 527386J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.
Ref 527386J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.